To determine possible synergy between erdafitinib and quisinostat in FGFR3 fusion-positive BC, we treated all three BC cells with erdafitinib and/or quisinostat for 3 days and then examined cell viability by WST-1 assay. Here, FGFR3 is linked to breast cancer.